Efficacy and safety of diflunisal therapy in patients with transthyretin cardiac amyloidosis (ATTR-CA): a systematic review and meta-analysis.

ABSTRACT:

Background

Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive cause of diastolic heart failure associated with poor prognosis. Currently available treatment, tafamidis, a TTR stabilizer, is highly effective and tolerable but is not cost-effective. Hence, we aim to evaluate the efficacy and safety of a mechanistically similar but more affordable TTR stabilizer, diflunisal, in patients with ATTR-CA.

Methods

Systematic searching until June 2024 was done on 3 databases to include patients with ATTR-CA of any type (hereditary or wild-type). Efficacy and safety of diflunisal are assessed by baseline to follow-up mean difference of specific clinical parameters and mortality risk reduction comparing intervention to the control group is evaluated by the generic inverse vari

SUBMITTER: Huang W 

PROVIDER: S-EPMC11896961 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature